Trending
•Ravi Mehta on building reasoning models that actually reason•StellarPay raises $40M to make cross-border payments invisible•The state of AI agents in 2026: the year tools become teammates•Small models are eating the enterprise — and saving fortunes doing it•SaaS margins are back — but only for the top quartile•Europe's $500M+ megarounds are back — three in the last sixty days•The first 100 customers playbook — what actually works in 2026•Verdant Labs wants to turn carbon removal into an industry•Ravi Mehta on building reasoning models that actually reason•StellarPay raises $40M to make cross-border payments invisible•The state of AI agents in 2026: the year tools become teammates•Small models are eating the enterprise — and saving fortunes doing it•SaaS margins are back — but only for the top quartile•Europe's $500M+ megarounds are back — three in the last sixty days•The first 100 customers playbook — what actually works in 2026•Verdant Labs wants to turn carbon removal into an industry
BiotechSeries B
Helix Bio
Programmable gene therapies for inherited disease.
HQ
Bangalore, India
Founded
2022
Employees
64
Raised
$92.0M
Coverage
Interviews
Kavya Reddy: "Indian biotech doesn't need permission from Boston anymore"
After raising $60M from a mix of Indian and US investors, Kavya Reddy explains what changes when biotech finally has a credible non-US home base.
Priya Sharma·
Funding
Helix Bio raises $60M for inherited-disease gene therapy
An Indian sovereign-linked fund led the round, with two US healthcare VCs participating. The capital plan: three concurrent clinical programs.
Marcus Chen·